Indacaterol for Chronic Obstructive Pulmonary Disease: Systematic Review and Meta-Analysis

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  Chung, Vincent C H ^a   Ma, Polly H X ^a   Hui, David S C ^a   Tam, Wilson W S ^a   Tang, Jin Ling ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

FORMOTEROL; INDACATEROL; PLACEBO; SALMETEROL; TIOTROPIUM BROMIDE;

ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COUGHING; DISEASE EXACERBATION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; FORCED EXPIRATORY VOLUME; HUMAN; META ANALYSIS; MORTALITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHINOPHARYNGITIS; SIDE EFFECT; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

BRONCHODILATOR AGENTS; HUMANS; INDANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUINOLONES; SCOPOLAMINE DERIVATIVES; TREATMENT OUTCOME;

EID: 84881532363     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0070784     Document Type: Article

References (46)

1. Mannino DM, Buist AS, (2007) Global burden of COPD: risk factors, prevalence, and future trends. Lancet 370: 765-73.
2. Michaud CM, Murray CJ, Bloom BR, (2001) Burden of disease-implications for future research. JAMA 285: 535-9.
3. Bustacchini S, Chiatti C, Furneri G, Lattanzio F, Mantovani LG, (2011) The economic burden of chronic obstructive pulmonary disease in the elderly: results from a systematic review of the literature. Curr Opin Pulm Med 17(S1): S35-41.
4. Qaseem A, Wilt TJ, Weinberger SE, Hanania NA, Criner G, et al. (2011) Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society. Ann Intern Med 155: 179-91.
5. Vestbo J, Hurd SS, Agusti AG, Jones PW, Vogelmeier C, et al. (2013) Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease, GOLD executive summary. Am J Respir Crit Care Med 187: 347-65.
6. Chowdhury BA, Seymour SM, Michele TM, Durmowicz AG, Liu D, et al. (2011) The risks and benefits of indacaterol-the FDA's review. N Engl J Med 365: 2247-9.
7. Haynes RB, Wilczynski NL, (2004) Optimal search strategies for retrieving scientifically strong studies of diagnosis from Medline: analytical survey. BMJ 328: 1040.
8. Wong SSL, Wilczynski NL, Haynes RB, (2006) Developing optimal search strategies for detecting clinically sound treatment studies in EMBASE.J Med Lib Asso. 94: 41.
9. Chan AW, (2012) Out of sight but not out of mind: how to search for unpublished clinical trial evidence. BMJ 344: d8013.
10. Martinez FJ, Donohue JF, Rennard SI, (2011) The future of chronic obstructive pulmonary disease treatment-difficulties of and barriers to drug development. Lancet 378: 1027-37.
11. Higgins JPT, Altman DG, Gøtzsche PC, Jüni P, Moher D, et al. (2011) The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 343: d5928.
12. Sterne JAC, Sutton AJ, Ioannidis JPA, Terrin N, Jones DR, et al. (2011) Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ 343: d4002.
13. Higgins J, Thompson SG, Deeks JJ, Altman DG, (2003) Measuring inconsistency in meta-analyses. BMJ 327: 557-60.
14. Cazzola M, MacNee W, Martinez F, Rabe K, Franciosi L, et al. (2008) Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J 31: 416-69.
15. Witek T, Mahler D, (2003) Minimal important difference of the transition dyspnoea index in a multinational clinical trial. Eur Respir J 21: 267-72.
16. Jones PW, (2005) St. George's Respiratory Questionnaire: MCID. COPD 2: 75-9.
17. Cote C, Celli B, (2005) Pulmonary rehabilitation and the BODE index in COPD. Eur Respir J 26: 630-6.
18. Feldman G, Siler T, Prasad N, Jack D, Piggott S, et al. (2010) Efficacy and safety of indacaterol 150 microg once-daily in COPD: a double-blind, randomised, 12-week study. BMC Pulm Med 10: 11.
19. Kerwin EM, Gotfried MH, Lawrence D, Lassen C, Kramer B, (2011) Efficacy and Tolerability of Indacaterol 75 mug Once Daily in Patients Aged > = 40 Years With Chronic Obstructive Pulmonary Disease: Results From 2 Double-Blind, Placebo-Controlled 12-Week Studies. Clin Ther 33: 1974-84.
20. Kinoshita M, Lee SH, Hang LW, Ichinose M, Hosoe M, et al. (2012) Efficacy and safety of indacaterol 150 and 300 μg in chronic obstructive pulmonary disease patients from six Asian areas including Japan: A 12-week, placebo-controlled study. Respirology 17: 379-89.
21. Korn S, Kerwin E, Atis S, Amos C, Owen R, et al. (2011) Indacaterol once-daily provides superior efficacy to salmeterol twice-daily in COPD: a 12-week study. Respir Med 105: 719-26.
22. To Y, Nishimura M, Fukuchi Y, Kitawaki T, Okino N, et al. (2011) Long-term safety and tolerability of indacaterol versus salmeterol in Japanese COPD patients: A 52-week open labeled study. Respirology.Conference: 16th Congress of the Asian Pacific Society of Respirology Shanghai China.Conference Start: 20111103 Conference End: 20111106.Conference Publication: (Var.Pagings) 16: 96.
23. Kornmann O, Dahl R, Centanni S, Dogra A, Owen R, et al. (2011) INLIGHT-2 (Indacaterol Efficacy Evaluation Using 150-microg Doses with COPD Patients) study investigators. Once-daily indacaterol versus twice-daily salmeterol for COPD: a placebo-controlled comparison. Eur Respir J 37: 273-9.
24. Buhl R, Dunn LJ, Disdier C, Lassen C, Amos C, et al. (2011) Blinded 12-week comparison of once-daily indacaterol and tiotropium in COPD. Eur Respir J 38: 797-803.
25. Donohue JF, Fogarty C, Lotvall J, Mahler DA, Worth H, et al. (2010) Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. Am J Respir Crit Care Med 182: 155-62.
26. Mahler A, D'Urzo A, Bateman E, Ozkan S, White T, et al. (2012) Concurrent use of indacaterol plus tiotropium in patients with COPD provides superior bronchodilation compared with tiotropium alone. Thorax 67: 781-8.
27. Dahl R, Chung KF, Buhl R, Magnussen H, Nonikov V, et al. (2010) Bleasdale P. Owen R. Higgins M. Kramer B. INVOLVE (INdacaterol: Value in COPD: Longer Term Validation of Efficacy and Safety) Study Investigators. Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPD. Thorax 65: 473-9.
28. Wood L, Egger M, Gluud LL, Schulz KF, Jüni P, et al. (2008) Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. BMJ 336: 601-5.
29. Bourbeau J, Bartlett SJ, (2008) Patient adherence in COPD. Thorax 63: 831-8.
30. Vestbo J, Anderson JA, Calverley PM, Celli B, Ferguson GT, et al. (2009) Adherence to inhaled therapy, mortality and hospital admission in COPD. Thorax 64: 939-43.
31. Barr RG, Bourbeau J, Camargo CA (2005) Tiotropium for stable chronic obstructive pulmonary disease. Cochrane Lib Issue 2. Art. No.: CD002876. doi:10.1002/14651858.CD002876.pub2.
32. Suissa S, Dell'Aniello S, Ernst P, (2012) Long-term natural history of chronic obstructive pulmonary disease: severe exacerbations and mortality. Thorax 67: 957-63.
33. Vogelmeier C, Hederer B, Glaab T, Schmidt H, Rutten-van Molken MP, et al. (2011) Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N Engl J Med 364: 1093-103.
34. Wang J, Jin D, Zuo P, Wang T, Xu Y, et al. (2011) Comparison of tiotropium plus formoterol to tiotropium alone in stable chronic obstructive pulmonary disease: a meta-analysis. Respirology 16: 350-8.
35. Karner C, Cates CJ (2012) Long-acting beta2-agonist in addition to tiotropium versus either tiotropium or long-acting beta2-agonist alone for chronic obstructive pulmonary disease. Cochrane Database Syst Rev Issue 4. Art. No.: CD008989. doi:10.1002/14651858.CD008989.pub2.
36. Cope S, Kraemer M, Zhang J, Capkun-Niggli G, Jansen JP, (2012) Efficacy of indacaterol 75 μg versus fixed-dose combinations of formoterol-budesonide or salmeterol-fluticasone for COPD: a network meta-analysis. Int J Chron Obstruct Pulmon Dis 7: 415-20.
37. Jones PW, Mahler DA, Gale R, Owen R, Kramer B, (2011) Profiling the effects of indacaterol on dyspnoea and health status in patients with COPD. Respir Med 105: 892-9.
38. Bleecker ER, Siler T, Owen R, Kramer B, (2011) Bronchodilator efficacy and safety of indacaterol 150 μg once daily in patients with COPD: an analysis of pooled data. Int J Chron Obstruct Pulmon Dis 6: 431-8.
39. Chapman K, Rennard S, Dogra A, Owen R, Lassen C, et al. (2011) Long-term safety and efficacy of indacaterol, a long-acting β2-agonist, in subjects with COPD: a randomized, placebo-controlled study. Chest 140: 68-75.
40. Cope S, Zhang J, Williams J, Jansen J, (2012) Efficacy of once-daily indacaterol 75 mug relative to alternative bronchodilators in COPD: A study level and a patient level network meta-analysis. BMC Pulm Med 12: 29.
41. Rodrigo GJ, Neffen H, (2012) Comparison of Indacaterol with tiotropium or twice daily long acting beta-agonists for stable COPD: A systematic review. Chest 142: 1104-10.
42. Donohue JF, Singh D, Kornmann O, Lawrence D, Lassen C, et al. (2011) Safety of indacaterol in the treatment of patients with COPD. Int J Chron Obstruct Pulmon Dis 6: 477.
43. Brienza NS, Amor-Carro O, Ramos-Barbon D, (2011) An update on the use of indacaterol in patients with COPD. Ther Adv Respir Dis 5: 29-40.
44. Lundh A, Sismondo S, Lexchin J, Busuioc OA, Bero L (2012) Industry sponsorship and research outcome. Cochrane Database Syst Rev Issue 12. Art. No.: MR000033. doi:10.1002/14651858.MR000033.pub2.
45. Hart B, Lundh A, Bero L, (2012) Effect of reporting bias on meta-analyses of drug trials: reanalysis of meta-analyses. BMJ 344: d7202.
46. Vogelmeier CF, Bateman ED, Pallante J, Alagappan VK, D'Andrea P, et al. (2013) Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study. Lancet Respir Med 1: 51-60.